News Release

Mallinckrodt to Present at Piper Jaffray 26th Annual Healthcare Conference in New York

DUBLIN--(BUSINESS WIRE)--Dec. 1, 2014-- Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical and global medical imaging company, will present at the Piper Jaffray 26th Annual Healthcare Conference in New York on Wednesday, December 3, 2014. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 11 a.m. Eastern.

Individuals who cannot attend the meeting can find webcast information on Mallinckrodt’s Investor Relations website or at: A replay will also be available following the meeting.


Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment include contrast media and nuclear imaging agents. Mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company’s fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit

Source: Mallinckrodt

Rhonda Sciarra, 314-654-8618
Manager, Communications
Meredith Fischer, 314-654-3318
Senior Vice President, Communications
John Moten, 314-654-6650
Vice President, Investor Relations